RxDoctor Payments Data

Marandapalli Sridharan, MD

Cardiovascular Disease · Augusta, GANPI 1376562231

Payments from drug & device makers

$464in general payments, 2019–2025

Across 29 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$116
  • Lexicon Pharmaceuticals, Inc.$85
  • Boston Scientific$55
  • Novartis$50
  • E.r. Squibb & Sons, L.L.C.$47
  • Novo Nordisk$38
  • plus $74 from 4 others

What the payments were for

  • Food & beverage$464100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$464 in reported general payments places this provider in the 20th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$224,453
Medicare patients
1,369
Services billed
2,791

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan201$216,817
EliquisApixaban203$199,030
XareltoRivaroxaban63$47,139
Repatha SureclickEvolocumab28$25,057
FarxigaDapagliflozin Propanediol18$24,655
Flecainide Acetate67$3,656
Ranolazine ErRanolazine49$3,427
Metoprolol Succinate263$3,074
Rosuvastatin Calcium229$2,332
Atorvastatin Calcium260$1,973
Amiodarone Hcl110$1,837
Diltiazem 24hr Er (Cd)Diltiazem Hcl34$1,502
Ezetimibe99$1,481
FenofibrateFenofibrate,micronized12$1,137
FenofibrateFenofibrate Nanocrystallized26$1,067

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$50$216,817201 claims
PfizerEliquis$116$199,030203 claims
Johnson & JohnsonXarelto$11$47,13963 claims
AstraZenecaFarxiga$32$24,65518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →